SG10201502398RA - Stable MIA/CD-RAP formulations - Google Patents

Stable MIA/CD-RAP formulations

Info

Publication number
SG10201502398RA
SG10201502398RA SG10201502398RA SG10201502398RA SG10201502398RA SG 10201502398R A SG10201502398R A SG 10201502398RA SG 10201502398R A SG10201502398R A SG 10201502398RA SG 10201502398R A SG10201502398R A SG 10201502398RA SG 10201502398R A SG10201502398R A SG 10201502398RA
Authority
SG
Singapore
Prior art keywords
mia
rap
formulations
stable
stable mia
Prior art date
Application number
SG10201502398RA
Inventor
Klaus Hellerbrand
Rainer Sigl
Original Assignee
Scil Technology Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scil Technology Gmbh filed Critical Scil Technology Gmbh
Publication of SG10201502398RA publication Critical patent/SG10201502398RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
SG10201502398RA 2010-04-27 2011-04-27 Stable MIA/CD-RAP formulations SG10201502398RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10161160 2010-04-27

Publications (1)

Publication Number Publication Date
SG10201502398RA true SG10201502398RA (en) 2015-05-28

Family

ID=43806879

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201908916U SG10201908916UA (en) 2010-04-27 2011-04-27 Stable MIA/CD-RAP formulations
SG2012064804A SG183561A1 (en) 2010-04-27 2011-04-27 Stable aqueous mia/cd-rap formulations
SG10201502398RA SG10201502398RA (en) 2010-04-27 2011-04-27 Stable MIA/CD-RAP formulations

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201908916U SG10201908916UA (en) 2010-04-27 2011-04-27 Stable MIA/CD-RAP formulations
SG2012064804A SG183561A1 (en) 2010-04-27 2011-04-27 Stable aqueous mia/cd-rap formulations

Country Status (20)

Country Link
US (2) US9511116B2 (en)
EP (1) EP2563809B1 (en)
JP (2) JP2013525406A (en)
KR (1) KR101880905B1 (en)
CN (1) CN102869679B (en)
AU (1) AU2011247659B2 (en)
BR (1) BR112012027361A2 (en)
CA (1) CA2792965A1 (en)
CL (1) CL2012002948A1 (en)
CO (1) CO6592098A2 (en)
HK (1) HK1179273A1 (en)
IL (1) IL222712B (en)
MA (1) MA34225B1 (en)
MX (1) MX344732B (en)
MY (1) MY160916A (en)
NZ (1) NZ601927A (en)
RU (2) RU2739078C2 (en)
SG (3) SG10201908916UA (en)
WO (1) WO2011134979A2 (en)
ZA (1) ZA201206235B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201908916UA (en) * 2010-04-27 2019-11-28 Scil Tech Gmbh Stable MIA/CD-RAP formulations
JPWO2014098232A1 (en) * 2012-12-21 2017-01-12 学校法人東京理科大学 PHARMACEUTICAL COMPOSITION CONTAINING PI3 KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING COMPOUND HAVING VITAMIN D RECEPTOR, LYophilized Composition, Method for Producing Lyophilized Composition, and Pharmaceutical Composition for Transpulmonary Administration
US10206878B2 (en) * 2014-05-28 2019-02-19 Nono Inc. Lyophilized formulation of TAT-NR2B9C with acetylation scavenger
CN108602866A (en) * 2015-09-18 2018-09-28 生命制药有限责任公司 Expression and folding in CD-RAP preparation process is improved by using CD-RAP precursor proteins
KR20190027878A (en) * 2016-07-13 2019-03-15 리폼 바이오로직스, 엘엘씨 Stabilizing excipients for therapeutic protein preparations
US11142553B2 (en) 2016-11-29 2021-10-12 Spiber Inc. Protein composition, method for producing same and method for improving heat stability
KR20190129061A (en) * 2017-03-31 2019-11-19 메이지 세이카 파루마 가부시키가이샤 Aqueous formulations and aqueous formulations in syringes, and antibody protein deagglomerates and antibody protein deagglomeration methods
KR20190066941A (en) 2017-12-06 2019-06-14 주식회사 에코에너젠 Reduction apparatus for complex pollutants from semiconductor process
CN112386575B (en) * 2019-08-19 2023-03-21 鲁南制药集团股份有限公司 Freeze-dried preparation of metabolism regulation fusion protein
KR102427935B1 (en) 2022-05-23 2022-08-03 주식회사 동우이엔티 Wet electrostatic precipitation system capable of simultaneous treatment of complex gas mixed with particulate and gaseous pollutants including wet scrubber

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54147916A (en) * 1978-05-12 1979-11-19 Sumitomo Chem Co Ltd Preparation of urokinase injection
DE2916711A1 (en) 1979-04-25 1980-11-06 Behringwerke Ag Blood coagulation factors and process for their manufacture
US4783441A (en) 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
US4374763A (en) * 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
EP0158487B1 (en) 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
FR2684878B1 (en) * 1991-12-12 1994-02-11 Roussel Uclaf STABILIZED PHARMACEUTICAL COMPOSITION OF RECOMBINANT, NON-GLYCOSYLATED HUMAN IL2 IN REDUCED FORM AND PROCESS FOR PREPARING THE SAME.
DE4242863A1 (en) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stable lyophilized pharmaceutical preparations of G-CSF
WO1995003328A2 (en) 1993-07-20 1995-02-02 Boehringer Mannheim Gmbh Melanoma-inhibiting protein
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
PT1516628E (en) * 1995-07-27 2013-09-24 Genentech Inc Stable isotonic lyophilized protein formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO2000012762A1 (en) 1998-09-01 2000-03-09 Millennium Pharmaceuticals, Inc. A novel protein related to melanoma-inhibiting protein and uses thereof
US20020103360A1 (en) 1998-09-01 2002-08-01 Yang Pan Novel protein related to melanoma-inhibiting protein and uses thereof
EP1025871A1 (en) 1999-01-28 2000-08-09 F. Hoffmann-La Roche Ag Use of a melanoma inhibiting activity factor (MIA) for cartilage and bone repair
CZ299516B6 (en) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof
RU2197238C2 (en) * 1999-11-22 2003-01-27 Российский научный центр "Восстановительная травматология и ортопедия" им. академика Г.А. Илизарова Method of prophylaxis and treatment of osteoarthrosis, agent for its realization and method of preparing agent for osteoarthrosis treatment
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
WO2001055332A2 (en) 2000-01-25 2001-08-02 Hyseq, Inc. Methods and materials relating to novel growth regulatory-like polypeptides and polynucleotides
IL150679A0 (en) * 2000-03-23 2003-02-12 Akzo Nobel Nv Use of mia in immunotherapy
JP2005521640A (en) * 2001-11-13 2005-07-21 ジェネンテック・インコーポレーテッド Apo-2 ligand / TRAIL formulation
EP1478394B1 (en) * 2002-02-27 2008-07-30 Immunex Corporation Stabilized TNFR-Fc composition comprising arginine
AU2003259696A1 (en) * 2002-08-08 2004-02-25 Nuvelo, Inc. Methods and materials relating to novel growth regulatory-like polypeptides and polynucleotides
DE10360483B4 (en) 2003-12-22 2007-11-15 Scil Proteins Gmbh Expression vector and its use
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
PT2081551E (en) * 2006-10-06 2013-02-18 Scil Technology Gmbh Dried reconstituted vesicle formation for pharmaceutical application
WO2008086395A2 (en) * 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
SG10201908916UA (en) * 2010-04-27 2019-11-28 Scil Tech Gmbh Stable MIA/CD-RAP formulations

Also Published As

Publication number Publication date
EP2563809B1 (en) 2020-04-01
RU2016118646A3 (en) 2019-06-20
AU2011247659B2 (en) 2014-07-24
MY160916A (en) 2017-03-31
RU2016118646A (en) 2018-11-02
IL222712A0 (en) 2012-12-31
WO2011134979A2 (en) 2011-11-03
NZ601927A (en) 2013-07-26
EP2563809A2 (en) 2013-03-06
CN102869679A (en) 2013-01-09
US20130137639A1 (en) 2013-05-30
IL222712B (en) 2018-02-28
JP2013525406A (en) 2013-06-20
MA34225B1 (en) 2013-05-02
CN102869679B (en) 2015-11-25
BR112012027361A2 (en) 2021-04-27
CL2012002948A1 (en) 2013-02-15
CA2792965A1 (en) 2011-11-03
AU2011247659A1 (en) 2012-09-06
KR101880905B1 (en) 2018-07-23
RU2012144771A (en) 2014-06-10
US9907829B2 (en) 2018-03-06
RU2588658C2 (en) 2016-07-10
MX2012012115A (en) 2013-01-29
HK1179273A1 (en) 2013-09-27
SG183561A1 (en) 2012-09-27
SG10201908916UA (en) 2019-11-28
US20170042971A1 (en) 2017-02-16
WO2011134979A3 (en) 2012-06-14
JP6078129B2 (en) 2017-02-08
JP2016034958A (en) 2016-03-17
WO2011134979A9 (en) 2012-08-16
MX344732B (en) 2017-01-04
CO6592098A2 (en) 2013-01-02
RU2739078C2 (en) 2020-12-21
KR20130086531A (en) 2013-08-02
ZA201206235B (en) 2021-04-28
US9511116B2 (en) 2016-12-06

Similar Documents

Publication Publication Date Title
IL223206A0 (en) Vaccine formulations
IL225415A0 (en) Electrolyte formulations
SG10201502398RA (en) Stable MIA/CD-RAP formulations
EP2547333A4 (en) Stable bortezomib formulations
SI2603232T1 (en) Stable formulations of linaclotide
GB201009368D0 (en) Dietary formulations
SI2605757T1 (en) Nalbuphine-based formulations and uses thereof
IL225892A0 (en) Formulations comprising polyethylene glycol
EP2582396A4 (en) Long lasting drug formulations
GB201002419D0 (en) Stable live vaccine formulations
ZA201300194B (en) Formulations
GB201110193D0 (en) Formulations
GB201013513D0 (en) Formulations
ZA201300196B (en) Formulations
GB201018647D0 (en) Formulations
GB201018645D0 (en) Formulations
GB201018649D0 (en) Formulations
GB201018648D0 (en) Formulations
GB201012589D0 (en) Formulations
GB201010494D0 (en) Formulations
GB201008470D0 (en) Formulations
GB201008358D0 (en) Formulations
GB201007959D0 (en) Formulations
GB201007702D0 (en) Formulations
GB201005587D0 (en) Novel formulations